Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool

Journal of Clinical Oncology

Volumn 13, Issue 3, 1995, Pages 765-782

  Gasparini, Giampietro ^a   Harris, Adrian L ^b  

^a St Bortolo Medical Centre   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYMANNONOJIRIMYCIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; BUMETANIDE; CD31 ANTIGEN; CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; FUROSEMIDE; GROWTH FACTOR; INTERLEUKIN 2; MINOCYCLINE; MONOCLONAL ANTIBODY; PENICILLAMINE; PENTOSAN POLYSULFATE; PROGESTERONE; PROTAMINE; RAZOXANE; RECOMBINANT THROMBOCYTE FACTOR 4; RETINOID; ROQUINIMEX; SURAMIN; TAMOXIFEN; THALIDOMIDE; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BASEMENT MEMBRANE; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULAR ENDOTHELIUM;

EID: 0028939826     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.3.765     Document Type: Review

References (198)

1. Dexter DL, Kowalsky HM, Blazer BA, et al: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38:3174-3181, 1978
2. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993 (review)
3. Fentiman IS, Mansel RE: The axilla: Not a no-go zone. Lancet 337:221-223, 1991
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
5. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer patients. N Engl J Med 326:1756-1761, 1992 (review)
6. Mason BH, Holdaway IM, Mullins PR, et al: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43:2985-2990, 1983
7. Predine J, Spyratos F, Prud'Homme JF, et al: Enzyme-linked immunosorbent assay of pS2 in breast cancer, benign tumors, and normal breast tissues. Cancer 69:2116-2123, 1992
8. Foekens JA, van Putten WLJ, Portengen H, et al: Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 11:899-908, 1993
9. Boring CC, Squires TS, Tong T: Cancer statistics, 1993. CA Cancer J Clin 43:7-26, 1993
10. Lippman ME: The development of biological therapies for breast cancer. Science 259:631-632, 1993
11. Chabner BA: Biological basis for cancer treatment. Ann Intern Med 118:633-637, 1993
12. Workman P, D'Incalci M, Berdel WE, et al: New approaches in cancer pharmacology: Drug design and development. Eur J Cancer 28A:1190-1200, 1992
13. Wagner RW, Matteucci MD, Lewis JG, et al: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260:1510-1513, 1993
14. Frei E III: Gene deletion: A new target for cancer chemotherapy. Lancet 342:662-664, 1993
15. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
16. Folkman J, Cole P, Zimmerman S: Tumor behavior in isolated perfused organs: in vitro growth and metastasis of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164:491-502, 1966
17. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
18. Bosari S, Lee AKC, DeLellis RA, et al: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
19. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371-374, 1993
20. Folkman J: Diagnostic and therapeutic applications of angiogenesis research. C R Acad Sci Paris III 316:914-918, 1993 (review)
21. Folkman J: Introduction: Angiogenesis and cancer. Semin Cancer Biol 3:47-48, 1992
22. Wagner RC: Endothelial cell embryology and growth. Adv Microcirc 9:45-75, 1980
23. Hunt TK: Wound Repair and Wound Infection: Theory and Surgical Practice. New York, NY, Appleton-Century-Crofts, 1980
24. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46:467-475, 1986
25. Hobson B, Denekamp J: Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49:405-413, 1984
26. Folkman J: Tumor angiogenesis, in Holland J, Frei E III, Bast RC, et al (eds): Cancer Medicine. Melbourne, PA, 1993, pp 153-170
27. Dvorak HF, Nagy JA, Dvorak AM: Structure of solid tumors and their vasculature: Implications for therapy with monoclonal antibodies. Cancer Cells 3:77-85, 1991
28. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267:10931-10934, 1992 (mini review)
29. Sillman F, Boyce J, Fruchter R: The significance of atypical vessels and neovascularization in cervical neoplasia. Am J Osbtet Gynecol 139:154-159, 1981
30. Smith-McCune KK, Weidner N: Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 54:800-804, 1994
31. Brem SS, Gullino PM, Medina D: Angiogenesis: A marker for neoplastic transformation of mammary papillary hyperplasia. Science 195:880-882, 1977
32. Srivastava A, Laidler P, Davies R, et al: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. Am J Pathol 133:419-423, 1988
33. Weidner N, Semple SP, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
34. Algire GH, Chalkley HW, Legallais FY, et al: Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions in mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6:73-85, 1945
35. Gimbrone MA, Leapman SB, Cotran RS, et al: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261-276, 1972
36. Gimbrone MA, Cotran RS, Leapman SB, et al: Tumor growth and neovascularization: An experimental model using the rabbit cornea. J Natl Cancer Inst 52:413-417, 1974
37. Knighton D, Ausprunk D, Tapper D, et al: Avascular and vascular phases of tumor growth in the chick embryo. Br J Cancer 35:347-356, 1977
38. Folkman J, Watson K, Ingber D, et al: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61, 1989
39. Kandel J, Bossy-Wetzel E, Radvanyi F, et al: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095-1104, 1991
40. Lien W, Ackerman N: The blood supply of experimental liver metastases: II. A microcirculatory study of normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery 68:334-340, 1970
41. V mice exhibit a decrease rate of tumor angiogenesis. Int J Cancer 42:48-52, 1988
42. Liotta L, Kleinerman J, Saldel G: Quantitative relationship of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34:997-1004, 1974
43. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188, 1994 (minireview)
44. Gasparini G, Weidner N, Maluta S, et al: Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 55:739-744, 1993
45. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:1-9, 1993
46. Gasparini G, Weidner N, Bevilacqua P, et al: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994
47. Ingber D, Fujita T, Kishimoto S, et al: Angioinhibins: Synthetic analogues of fumagallin which inhibit angiogenesis and suppress tumour growth. Nature 348:555-557, 1990
48. Hori A, Sasada R, Matsutami E, et al: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51:6180-6184, 1991
49. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
50. Burrows FJ, Thorpe PE: Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90:8996-9000, 1993
51. 3 for angiogenesis. Science 264:569-571, 1994
52. Millauer B, Shawver LK, Plate KH, et al: Glioblastoma growth inhibited in vivo by a dominant-negative FIK-1 mutant. Nature 367:576-579, 1994
53. Ezekowitz RA, Mullikan JB, Folkman J: Interferon alpha-2a therapy for "life-threatening" hemangiomas of infancy. N Engl J Med 326:1456-1463, 1992
54. Craft PS, Harris AL: Clinical prognostic significance of tumour angiogenesis. Ann Oncol 5:305-311, 1994 (review)
55. Goto F, Goto K, Weindel F, et al: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor in the bovine capillary endothelial cells within collagen gels. Lab Invest 69:508-517, 1993
56. Leibovich SJ, Polverini PJ, Shepard HM: Macrophage-induced angiogenesis mediated by tumour necrosis factor-alpha. Nature 329:630-634, 1987
57. Rastinejad F, Polverini PJ, Bouck NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56:345-355, 1989
58. Kieser A, Weich HA, Brandner G, et al: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969, 1994
59. Dameron KM, Volpert OV, Tainsky MA, et al: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1585, 1994
60. D'Amore PA: Capillary growth: A two-cell system. Semin Cancer Biol 3:49-56, 1992 (review)
61. Taylor S, Folkman J: Protamine is an inhibitor of angiogenesis. Nature 297:307-312, 1982
62. Bouck NP: Tumor angiogenesis: The role of oncogenes and tumor suppressor genes. Cancer Cell 2:179-185, 1990
63. Hamada J, Carmaugh PG, Lotan O, et al: Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 66:349-354, 1992
64. Rak JW, Hegman E, Lu C, et al: Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J Cell Physiol 159:245-255, 1994
65. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
66. Gimbrone MA Jr, Gullino PM: Neovascularization induced by intraocular xenografts of normal, preneoplastic, and neoplastic mouse mammary tissues. J Natl Cancer Inst 56:305-318, 1976
67. Brem SS, Jensen HM, Gullino PM: Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 41:239-244, 1978
68. Jensen HM, Chen I, DeVault MR, et al: Angiogenesis induced by "normal" human breast tissue: A probable marker for precancer. Science 218:293-295, 1982
69. Guidi AJ, Fischer L, Harris JR, et al: Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86:614-619, 1994
70. Guinebretiere J-M, Le Monique G, Gavoille A, et al: Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 86:635-636, 1994 (letter)
71. Zajchowski DA, Band V, Trask DK, et al: Suppression of tumor-forming ability and related traits in MCF-7 human breast cancer cells by fusion with immortal mammary epithelial cells. Proc Natl Acad Sci USA 87:2314-2318, 1990
72. Arteaga CL, Cartydugger T, Moses HL, et al: Trasforming growth factor-beta(1) can induce estrogen-independent tumorigenicity of human breast-cancer cells in athymic mice. Cell Growth Differ 4:193-201, 1993
73. Costa M, Danesi R, Agen C, et al: Mcf-10a cells infected with the int-2 oncogene induce angiogenesis in the chick chorioallantoic membrane and in the rat mesentery. Cancer Res 54:9-11, 1994
74. Kurebayashi J, McLeskey SW, Johnson MD et al: Quantitative demonstration of spontaneos metastasis by mcf-7 human breast-cancer cells contrasfected with fibroblast growth factor-iv and lacz. Cancer Res 53:2178-2187, 1993
75. McLeskey SW, Kurebayashi J, Honig SF, et al: Fibroblast growth factor-iv transfection of mcf-7 cells produces cell-lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res 53:2168-2177, 1993
76. Marx J: Cellular changes on the route to metastasis. Science 259:626-629, 1993
77. Brem S, Cotran R, Folkman J: Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst 48:347-356, 1972
78. Weidner N: Factor VIII-related antigen (response). J Natl Cancer Inst 85:674-676, 1993 (letter)
79. Parums DV, Cordell JL, Micklem K, et al: JC70: A new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752-757, 1990
80. Wang JM, Kumar S, Pye D, et al: Breast carcinoma: Comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 86:386-388, 1994
81. Horak ER, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
82. Fox SB, Leek RD, Smith K, et al: Tumor angiogenesis in node-negative breast carcinomas - Relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29:109-116, 1994
83. Wang JM, Kumar S, Pye D, et al: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 54:363-370, 1993
84. Barbareschi M, Weidner N, Gasparini G, et al: Microvessel density quantification in breast carcinoma: A comparison between human counts and computer assisted image analysis. Appl Immunohistochem (in press)
85. 1 in the human mammary gland. Cancer Res 51:4685-4692, 1991
86. Reed JA, McNutt NS, Albino AP: Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Am J Pathol 144:329-336, 1994
87. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al: Expression of basic fibroblast growth factor in primary human renal tumors: Correlation with poor survival. J Natl Cancer Inst 85:1597-1599, 1993
88. Bianchi E, Cohen RL, Thor AT, et al: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54:861-866, 1994
89. Grondahl-Hansen J, Christensen IJ, Rasenquist C, et al: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosol extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521, 1993
90. Watanabe H, Hori A, Seno M, et al: A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun 175:229-235, 1991
91. Fujimoto K, Ichimori Y, Kakizoe T, et al: Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Commun 180:386-392, 1991
92. Nguyen M, Watanabe H, Budson AE, et al: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 85:241-242, 1993
93. Nguyen M, Watanabe, Budson AE, et al: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356-361, 1994
94. Ferrara N, Houck K, Jakeman L, et al: Molecular and biological prospectives of the vascular endothelial growth factor family of proteins. Endocrine Rev 13:18-32, 1992 (review)
95. Philip PA, Thompson CH, Carmichael J, et al: A phase-I study of the left-shifting agent bw12c79 plus mitomycin-c and the effect on the skeletal-muscle metabolism using p-31 magnetic-resonance spectroscopy. Cancer Res 53:5649-5653, 1993
96. Wu CC, Lee CN, Chen TM, et al: Incremental angiogenesis assessed by color doppler ultrasound in the tumorigenesis of ovarian neoplasms. Cancer 73:1251-1256, 1994
97. Locci M, Nazzaro G, Deplacido G, et al: Angiogenesis - A new diagnostic aspect of obstetric and gynecologic echography. J Perinat Med 21:453-473, 1993
98. Filho IPT, Leunig M, Yuan F, et al: Noninvasive measurament of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci USA 91:2081-2085, 1994
99. Fox SB, Gatter KC, Bicknell R, et al: Relationship of endothelial-cell proliferation to tumor vascularity in human breast-cancer. Cancer Res 53:4161-4163, 1993
100. Brien SE, Zagzag D, Brem S: Rapid in situ cellular kinetics of intracerebral tumor angiogenesis using a monoclonal-antibody to bromodeoxyuridine. Neurosurgery 25:715-719, 1989
101. Hall NR, Fish DE, Hunt N, et al: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1:223-229, 1992
102. Visscher DW, Smilanetz S, Drozdowicz S, et al: Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Analytical Quant Cytol Histol 15:88-92, 1993
103. Van Hoef MEHM, Knox WF, Dhesi SS, et al: Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A:1141-1145, 1993
104. Khanuja PS, Gimotty P, Fregene T, et al: Angiogenesis quantitation as a prognostic factor for primary breast carcinoma 2 cms or less, in Salmon SE (ed): Adjuvant Therapy of Cancer (ed VII). Philadelphia, PA, Lippincott, 1993, pp 226-232
105. Obermair A, Czervewenka K, Kunz C, et al: Influence of tumoral microvessel density on the recurrence-free survival in human breast cancer: Preliminary results. Onkologie 17:44-49, 1994
106. Toi M, Inada K, Suzuki H, et al: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat (in press)
107. Gasparini G: Quantification of intratumoral vascularisation predicts metastasis in human invasive solid tumours. Oncol Rep 1:7-12, 1994 (review)
108. Gasparini G, Bevilacqua P, Boracchi P, et al: Prognostic value of p53 expression in early-stage breast carcinoma compared with tumour angiogenesis, epidermal growth factor receptor, c-erbB-2, cathepsin D, DNA ploidy, parameters of cell kinetics and conventional features. Int J Oncol 4:155-162, 1994
109. Page DL, Dupont WD: Breast cancer angiohistogenesis: Through a narrow window. J Natl Cancer Inst 84:1850-1851, 1992 (editorial)
110. Liotta LA, Thorgeirsson UP, Garbisa S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1:277-288, 1982
111. Bacharach E, Itin A, Keshet E: In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in upregulating physiological angiogenesis. Proc Natl Acad Sci USA 89:10686-10690, 1992
112. Janicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostasis 17:303-332, 1991
113. Foekens JA, Schmitt M, vanPutten WLJ, et al: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994
114. Li V, Yu C, Rupnick M, et al: Serum from breast cancer patients contains proliferative activity for capillary endothelial cells which correlates with risk of mortality. Proc Am Soc Clin Oncol 12:113, 1993 (abstr 252)
115. Rossi C, Gasparini G, Canobbio L, et al: Doxorubicin distribution in human breast cancer. Cancer Treat Rep 71:1221-1226, 1987
116. Gasparini G, Toffoli G, Berlanda G, et al: A pharmacological rationale for neoadjuvant chemotherapy with Adriamycin in locally advanced breast cancer. Anticancer Res 10:193-196, 1990
117. Huang A, Wright JA: Fibroblast growth factor mediated alteractions in drug resistance, and evidence of gene amplification. Oncogene 9:491-499, 1994
118. Gagliardi A, Collins DC: Inhibition of angiogenesis by antiestrogens. Cancer Res 53:533-535, 1993
119. Gasparini G, Bevilacqua P, Pozza F, et al: P-glycoprotein expression predicts response to chemotherapy in previously untreated advanced breast cancer. Breast 2:27-32, 1993
120. Protopapa E, Delides GS, Revesz L: Vascular density and the response of breast cancer to mastectomy and adjuvant chemotherapy. Eur J Cancer 29A: 1391-1393, 1993
121. Yeo K-T, Wang HH, Nagy JA, et al: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53:2912-2918, 1993
122. Denekamp J: The current status of targeting tumour vasculature as a means of cancer therapy: An overview. Int J Radiat Biol 60:401-408, 1991
123. Gasparini G, Harris AL: Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur J Cancer 30A:201-206, 1994
124. Bicknell R, Harris AL: Anticancer strategies involving the vasculature: Vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol 3:399-407, 1992
125. Brem H, Folkman J: Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 141:427-429, 1975
126. Tanaka NG, Sakamoto N, Inove K, et al: Antitumor effect of an antiangiogenesis polysaccharide from an arthrobacter species with or without a steroid. Cancer Res 49:6727-6730, 1989
127. Pesenti E, Sola F, Mongelli N, et al: Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 66:367-372, 1992
128. Braddock PS, Hu D-E, Fan TDP, et al: A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 69:890-898, 1994
129. Vukanovic J, Passanti A, Hirata T, et al: Anti-angiogenic effects of the quinoline-3-carboxamide, linomide. Cancer Res 53:1833-1837, 1993
130. Maione TE, Gray GS, Petro J, et al: Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides. Science 247:77-79, 1990
131. Herbert JM, Cottineau M, Driot F, et al: Activity of pentosan polysuphate and derived compounds on vascular endothelial cell proliferation and migration induced by actid and basic FGF in vitro. Biochem Pharmacol 37:4281-4288, 1988
132. Matsubara T, Saura R, Hirohata K, et al: Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest 83:158-167, 1989
133. Fotsis T, Pepper M, Adlercreutz H, et al: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90:2690-2694, 1993
134. D'amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085, 1994
135. Panet R, Markus M, Atlan H: Bumetanide and furosemide inhibited vascular endothelial cell proliferation. J Cell Physiol 158:121-127, 1994
136. Nguyen M, Folkman J, Birchoff J: 1-Deoxymannojirimycin inhibits capillary tube formation in vitro. J Biol Chem 267:26157-26165, 1992
137. Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 52:672-675, 1991
138. Saiki I, Murata J, Nakajima M, et al: Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation of metastatic melanoma cells. Cancer Res 50:3631-3637, 1990
139. Folkman J, Ingber DE: Angiostatic steroids: Method of discovery and mechanism of action. Ann Surg 206:373-384, 1987
140. Folkman J, Weisz PB, Joullic MM, et al: Control of angiogenesis with synthetic heparin substitutes. Science 243:1490-1493, 1989
141. Ingber D, Folkman J: Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 59:44-51, 1988
142. Fuji T, Sujita N, Kobayashi Y, et al: Treatment with krestin combined with mitomycin C and effect on immuno response. Oncology 46:49-53, 1989
143. Karakiulakis G, Missirlis E, Maragoudakis ME: Mode of action of razoxane: Inhibition of basement membrane collagen-dyradation by a malignant tumor enzyme. Methods Fund Exp Clin Pharmacol 11:255-261, 1989
144. Potts M, Dopplet S, Taylor S: Protamine: A powerful in vivo inhibitor of bone resorption. Calcif Tissue Int 36:189-194, 1984
145. Davies B, Brown PD, East N, et al: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolong survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087-2091, 1993
146. Pienta KJ, Nguyen NM, Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretimide. Cancer Res 53:224-226, 1993
147. Takahashi K, Mulliken JB, Kozakewich HPW, et al: Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93:2357-2364, 1994
148. Karp JE, Broder S: New directions in molecular medicine. Cancer Res 54:653-665, 1994
149. Ishii H, Horic S, Kizaki K, et al: Retinoid acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured human endothelial cells expose to tumor necrosis factor. Blood 80:2556-2562, 1992
150. Sinkovics JG: Interferons: Antiangiogenesis agents (a reasonable theory). Can J Infect Dis 3:128B-132B, 1992 (suppl B)
151. Cozzolino F, Torcia M, Lucibello M, et al: Interferon alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest 91:2504-2512, 1993
152. Sinkovics JC: Oncogenes and growth factors. CRC Crit Rev Immunol 8:217-298, 1988
153. Knabbe C, Lippman ME, Wakefield L, et al: Evidence that TGF-beta is a hormonally regulated negative growth factor in human breast cancer. Cell 48:417-428, 1987
154. Noguchi S, Motomura K, Inaji H, et al: Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer 72:131-136, 1993
155. Gasparini G: Tamoxifen and chemotherapy in the treatment of metastatic melanoma: Are there other possible mechanisms explaining their potentiation? J Clin Oncol 12:1994-1996, 1994 (letter)
156. Toi M, Yamamoto Y, Imazawa T, et al: Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA-induced mammary tumors in rats. Int J Oncol 3:525-528, 1993
157. Killough JH, Magill GB, Smith RC: The treatment of amebiasis with suramin. Science 115:71-72, 1952
158. Danesi R, Del Bianchi S, Sodani P, et al: Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 68:932-938, 1993
159. Takano S, Gately S, Neville ME, et al: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type, plasminogen activator. Cancer Res 54:2654-2660, 1994
160. Vignon E, Prebois C, Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 84:38-42, 1992
161. Foekens J, Sieuwerts A, Stuurman-Smeets E, et al: Pleotropic actions of suramin on the proliferation of human breast-cancer cells in vitro. Int J Cancer 51:439-444, 1992
162. Myers C, Cooper M, Stein C, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889, 1992
163. La Rocca R, Cooper M, Stein C, et al: A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. Ann Oncol 3:371-373, 1992
164. Stein CA: Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53:2239-2248, 1993
165. Stein CA, La Rocca RV, Thomas R, et al: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508, 1989
166. La Rocca R, Cooper M, Stein C, et al: A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. Ann Clin Oncol 3:571-573, 1992
167. Reed E, Cooper MR, La Rocca RV: Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer 28A:864-866, 1992
168. Kusaka M, Sudo K, Matsutami E, et al: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69:212-216, 1994
169. Abe J, Zhou W, Takuwa N, et al: A fumagallin-derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product, but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 54:3407-3412, 1994
170. Antoine N, Greimers R, De Roanne C: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54:2073-2076, 1994
171. Yanase T, Tamura M, Fuijta K, et al: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53:2566-2570, 1993
172. Yamaoka M, Yamamoto T, Masaki T, et al: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470). Cancer Res 53:4262-4267, 1993
173. Levine SP, Wohl H: Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4. J Biol Chem 251:324-328, 1976
174. Sharpe RJ, Byers HR, Scott CF, et al: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82:848-853, 1990
175. Tai-Ping DF: Angiosuppressive therapy for cancer. Trends Pharmacol Sci 25:33-36, 1994
176. Joffe S: Drug prevention of postoperative deep vein thrombosis: A comparative study of calcium heparinate and sodium pentosan polysulfate. Arch Surg 111:37-40, 1976
177. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulphate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 84:1716-1724, 1992
178. Pluda JM, Shay LE, Foli A, et al: Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 85:1585-1592, 1993
179. Kalland T, Alm G, Stalhandske T: Augmentation of mouse natural killer cell activity by LS 2616 a new immunomodulator. J Immunol 134:3956-3961, 1985
180. Kalland T: Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 46:3018-3022, 1986
181. Ichikawa T, Lamb JC, Christensson PI: The antitumor effects of the quinoline-3-carboxamide linomide on dunning R-3327 rat prostatic cancers. Cancer Res 52:3022-3028, 1992
182. Bengston M, Simonsson B, Carlsson K, et al: Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. Transplantation 53:882-888, 1992
183. Hellman K, Gilbert J, Evans M, et al: Effect of razoxane on metastases from colorectal cancer. Clin Exp Metastasis 5:3-8, 1987
184. Le Serve AW, Hellmann K: Metastases and the normalization of tumour blood vessels by ICRF 159: A new type of drug action. Br Med J 1:597-601, 1972
185. Teicher BA, Sotomayor EA, Huang ZD, et al: Beta-cyclodextrin tetradecasulfate/tetrahydrocortisol ± minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic lewis lung carcinoma. Cancer Chemother Pharmacol 33:229-238, 1993
186. Kondo S, Yin D, Aoki T, et al: Bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells. Exp Cell Res 213:428-432, 1994
187. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991 (editorial)
188. Folkman J: Angiogenesis and breast cancer. J Clin Oncol 12:441-443, 1994 (editorial)
189. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
190. Teicher BA, Holden SA, Ara G, et al: Response to the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. Anticancer Res 13:2101-2106, 1993
191. Teicher BA, Holden SA, Ara G, et al: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57:920-925, 1994
192. Sotomayor EA, Teicher BA, Shwartz GN, et al: Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 30:377-384, 1992
193. Teicher BA, Holden SA, Dupuis NP, et al: Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat (in press)
194. Fuks Z, Persaud RS, Alfieri A, et al: Basic fibroblast growth factor protects endothelial cells against radiation-induced pro-grammed cell death in vitro and in vivo. Cancer Res 54:2582-2590, 1994
195. Haimovitz-Friedman A, Balaban N, Mc Loughlin M, et al: Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 54:2591-2597, 1994
196. Grzegorzewski K, Ruscetti FW, Usui N, et al: Recombinant transforming growth factor β1 and β2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med 180:1047-1057, 1994
197. Easton DF, Bishop DT, Ford D, et al: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Human Genet 52:678-701, 1993
198. Easton DF, Ford D, Bishop DT, et al: Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet (in press)